Compare · META vs TEM
META vs TEM
Side-by-side comparison of Meta Platforms Inc. (META) and Tempus AI Inc. (TEM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both META and TEM operate in Computer Software: Programming Data Processing (Technology), so they compete in similar markets.
- META is the larger of the two at $1.51T, about 180.6x TEM ($8.34B).
- TEM has been more active in the news (33 items in the past 4 weeks vs 32 for META).
- Both have 25 recent analyst ratings on file.
- Company
- Meta Platforms Inc.
- Tempus AI Inc.
- Price
- $588.05-0.81%
- $47.81+3.11%
- Market cap
- $1.51T
- $8.34B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Computer Software: Programming Data Processing
- Computer Software: Programming Data Processing
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2012
- 2024
- News (4w)
- 32
- 33
- Recent ratings
- 25
- 25
Meta Platforms Inc.
Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, personal computers, virtual reality headsets, wearables, and in-home devices worldwide. It operates in two segments, Family of Apps and Reality Labs. The Family of Apps segment's products include Facebook, which enables people to share, discover, and connect with interests; Instagram, a community for sharing photos, videos, and private messages, as well as feed, stories, reels, video, live, and shops; Messenger, a messaging application for people to connect with friends, family, groups, and businesses across platforms and devices through chat, audio and video calls, and rooms; and WhatsApp, a messaging application that is used by people and businesses to communicate and transact privately. The Reality Labs segment provides augmented and virtual reality related products comprising virtual reality hardware, software, and content that help people feel connected, anytime, and anywhere. The company was formerly known as Facebook, Inc. and changed its name to Meta Platforms, Inc. in October 2021. Meta Platforms, Inc. was incorporated in 2004 and is headquartered in Menlo Park, California.
Latest META
- Director Kimmitt Robert M sold $317,162 worth of shares (504 units at $629.29) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 3,943 units (SEC Form 4)
- Chief Operating Officer Olivan Javier sold $922,539 worth of shares (1,466 units at $629.29) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 12,986 units (SEC Form 4)
- Meta Platforms upgraded by Arete with a new price target
- SEC Form 144 filed by Meta Platforms Inc.
- AI's Power Crisis Is Accelerating a Potential $2.5 Trillion Hydrogen Market
- Chief Legal Officer Mahoney Curtis J. sold $1,268,024 worth of shares (2,079 units at $609.92) as part of a pre-agreed trading plan, decreasing direct ownership by 65% to 1,118 units (SEC Form 4)
- Meta Platforms Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Operating Officer Olivan Javier sold $892,765 worth of shares (1,466 units at $608.98) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 13,823 units (SEC Form 4)
- Meta Announces Quarterly Cash Dividend
- JLens Urges Meta Shareholders to Take Action Against Online Hate and Vote FOR Proposal 8 at the Annual Meeting on May 27, 2026
Latest TEM
- Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Director Epstein David R sold $12,350 worth of shares (250 units at $49.40) as part of a pre-agreed trading plan, decreasing direct ownership by 0.79% to 31,464 units (SEC Form 4)
- Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
- Wolfe Research resumed coverage on Tempus AI
- Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
- Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
- Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
- Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
- CEO and Chairman Lefkofsky Eric P sold $7,763,312 worth of shares (166,250 units at $46.70) as part of a pre-agreed trading plan (SEC Form 4)
- Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology